The COVID19 pandemic has forced more flexibility in order to keep existing trials running for those who need it most. Data and technology innovation remain at the forefront as biopharma clinical leaders seek to expedite outcomes, enhance patient experience, control cost, and improve efficiency in clinical trial phases. |